SCHEMBL5690378

SCHEMBL5690378

Cc1ccnc(Cc2ccc(OC(=O)N3CCC(Sc4nnnn4C)CC3)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
P2RX3 P56373 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TSHR P16473 2/20 0.34
BCHE P06276 2/20 0.33
CNR2 P34972 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 1/20 0.33
KDM5C P41229 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5931594 0.92 TSHR (0.37) NOS3NOS1NOS2TLR9TLR8
SCHEMBL5688888 0.89 NOS3 (0.34) NOS3NOS1NOS2TLR9TLR8
SCHEMBL5690369 0.89 NOS3 (0.34) NOS3NOS1NOS2TLR9TLR8
SCHEMBL5687565 0.89 NOS1 (0.35) NOS3NOS1NOS2TLR9TLR8
SCHEMBL5690568 0.88 ALDH1A1 (0.38) NOS3NOS1NOS2ALDH1A1P2RX3
SCHEMBL5687508 0.88 TDP1 (0.40) NOS2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5690077 0.87 ALDH1A1 (0.35) TLR9TLR8TLR7ALDH1A1KEAP1
SCHEMBL5688462 0.86 NOS1 (0.38) NOS3NOS1NOS2TLR9TLR8
SCHEMBL5687843 0.86 KMT2A (0.41) ALDH1A1KEAP1NFE2L2SMN1; SMN2TSHR
SCHEMBL5688311 0.84 CYP1A2 (0.41) ALDH1A1SMN1; SMN2NPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC NOS3 444/4885NOS1 646/4885NOS2 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.